Related Experiment Videos
Azathioprine. Safety profile in multiple sclerosis patients
L La Mantia1, N Mascoli, C Milanese
1Dipartimento di Neuroscienze, Multiple Sclerosis Center Fondazione IRCCS Istituto Neurologico C. Besta, Via Celoria 11, Milan, Italy. msgroup@istituto-besta.it
Summary
Azathioprine (Aza) is an effective treatment for multiple sclerosis (MS), but requires careful monitoring for adverse events like gastrointestinal issues and leukopenia. Long-term use may increase cancer risk, necessitating vigilant patient management.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Azathioprine (Aza) has been used for multiple sclerosis (MS) since 1971.
- Recent studies show its efficacy in reducing MRI lesion load, particularly in IFN-treated MS patients.
- Concerns regarding malignancy risk and unexpected adverse events (AEs) necessitate a safety profile review.
Purpose of the Study:
- To systematically review the safety profile of Azathioprine (Aza) in multiple sclerosis (MS) patients.
- To provide data supporting the clinical management of Aza therapy in MS.
- To assess the risk of cancer and reproductive toxicity associated with Aza treatment.
Main Methods:
- A systematic review of controlled and observational clinical studies published between 1971 and 2007.
- Registration and frequency calculation of adverse events (AEs).
- Consideration of cancer risk and reproductive toxicity.
Main Results:
- Gastrointestinal complaints and leukopenia are the most frequent AEs (>10%).
- Infections, allergy, anemia, thrombocytopenia, and pancytopenia are common (1-10%).
- Pancreatitis is uncommon (<1%); cancer risk increases with duration and dose.
Conclusions:
- Azathioprine (Aza) has an acceptable safety profile in MS when managed appropriately.
- Management strategies for AEs, adherence to dosage, and long-term cancer risk monitoring are crucial.
- No data on reproductive toxicity in MS patients treated with Aza are available.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.